| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| INCYIncyte Corporation | 20.66B | 105.24 | 701.60 | 14.76% | 24.69% | 25.55% | 1.21% | 0.01 |
| TGTXTG Therapeutics, Inc. | 4.88B | 30.71 | 204.73 | 40.8% | 13.31% | 21.87% | 1.14 | |
| AGIOAgios Pharmaceuticals, Inc. | 1.62B | 27.80 | 2.39 | 36.07% | -8.96% | -31.24% | 0.04 | |
| CLRBCellectar Biosciences, Inc. | 15.48M | 3.65 | -0.09 | -200.99% | 0.03 | |||
| CASICASI Pharmaceuticals, Inc. | 21.37M | 1.04 | -0.41 | -15.77% | -183.93% | -301.8% | 11.96 | |
| VORVor Biopharma Inc. | 308.06M | 14.06 | -0.41 | -94.52% | 0.33 | |||
| FATEFate Therapeutics, Inc. | 121.12M | 1.05 | -0.64 | -78.55% | -21.87% | -66.69% | 0.27 | |
| KPTIKaryopharm Therapeutics Inc. | 121.95M | 6.66 | -0.71 | -0.55% | -87.43% |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.67M | 6.33M | 6.81M | 14.51M | 12.45M | 27.91M | 209.71M | 221.98M | 980.65M |
| Revenue Growth % | - | -0.17% | 0.08% | 1.13% | -0.14% | 1.24% | 6.51% | 0.06% | 3.42% |
| Cost of Goods Sold | 261K | 0 | 0 | 2.1M | 1.97M | 3.33M | 22M | 30.54M | 29.09M |
| COGS % of Revenue | 0.03% | - | - | 0.14% | 0.16% | 0.12% | 0.1% | 0.14% | 0.03% |
| Gross Profit | 7.41M | 6.33M | 6.81M | 12.42M | 10.48M | 24.58M | 187.71M | 191.44M | 951.57M |
| Gross Margin % | 0.97% | 1% | 1% | 0.86% | 0.84% | 0.88% | 0.9% | 0.86% | 0.97% |
| Gross Profit Growth % | - | -0.15% | 0.08% | 0.82% | -0.16% | 1.34% | 6.64% | 0.02% | 3.97% |
| Operating Expenses | 122.03M | 137M | 330.65M | 595.1M | 674.42M | 894.42M | 1.04B | 1.06B | 1.32B |
| OpEx % of Revenue | 15.92% | 21.65% | 48.58% | 41% | 54.17% | 32.05% | 4.95% | 4.79% | 1.35% |
| Selling, General & Admin | 17.71M | 13.4M | 89.72M | 98.85M | 64.06M | 191.26M | 328.02M | 376.46M | 383.12M |
| SG&A % of Revenue | 2.31% | 2.12% | 13.18% | 6.81% | 5.15% | 6.85% | 1.56% | 1.7% | 0.39% |
| Research & Development | 102.69M | 118.81M | 249.56M | 463.88M | 564.57M | 766.49M | 743.1M | 706.97M | 947.25M |
| R&D % of Revenue | 13.39% | 18.78% | 36.66% | 31.96% | 45.35% | 27.46% | 3.54% | 3.18% | 0.97% |
| Other Operating Expenses | 1.63M | 4.78M | -8.63M | 32.37M | 45.8M | -63.34M | -33.6M | -19.36M | -9.07M |
| Operating Income | -114.62M | -130.67M | -50.25M | -582.68M | -663.94M | -869.84M | -849.81M | -872.64M | -369.73M |
| Operating Margin % | -14.95% | -20.65% | -7.38% | -40.15% | -53.33% | -31.17% | -4.05% | -3.93% | -0.38% |
| Operating Income Growth % | - | -0.14% | 0.62% | -10.6% | -0.14% | -0.31% | 0.02% | -0.03% | 0.58% |
| EBITDA | -114.46M | -118.17M | -31.78M | -578.86M | -646.98M | -852.65M | -802.39M | -779.44M | -276.56M |
| EBITDA Margin % | -14.93% | -18.67% | -4.67% | -39.89% | -51.97% | -30.55% | -3.83% | -3.51% | -0.28% |
| EBITDA Growth % | - | -0.03% | 0.73% | -17.21% | -0.12% | -0.32% | 0.06% | 0.03% | 0.65% |
| D&A (Non-Cash Add-back) | 164.37K | 12.5M | 18.46M | 3.83M | 16.96M | 17.18M | 47.42M | 93.19M | 93.17M |
| EBIT | -104.58M | -62.18M | -46.85M | -1.48B | -669.19M | -815.52M | -834.39M | -836.8M | -330.8M |
| Net Interest Income | -3.25M | -57.63M | -29.86M | 8.63M | -1.04M | -9.63M | -43.06M | -63.65M | -26.61M |
| Interest Income | 13K | 304K | 7.06M | 12.91M | 5.22M | 7.11M | 9.73M | 32.41M | 37.84M |
| Interest Expense | 3.26M | 57.94M | 36.92M | 4.27M | 6.25M | 16.73M | 52.78M | 96.06M | 64.45M |
| Other Income/Expense | 6.78M | 10.55M | -23.07M | -899.63M | -11.51M | 37.59M | -37.36M | -60.23M | -25.52M |
| Pretax Income | -107.84M | -120.12M | -346.91M | -1.48B | -675.45M | -832.25M | -887.17M | -932.86M | -395.25M |
| Pretax Margin % | -14.07% | -18.98% | -50.96% | -102.14% | -54.25% | -29.82% | -4.23% | -4.2% | -0.4% |
| Income Tax | 0 | -1.6M | -1.6M | -1.6M | 2.16M | -49.83M | -4.25M | -7.15M | 10.43M |
| Effective Tax Rate % | 1% | 0.99% | 1% | 1% | 1% | 0.94% | 1% | 0.99% | 1.03% |
| Net Income | -107.84M | -118.51M | -345.31M | -1.48B | -677.61M | -782.42M | -882.92M | -925.64M | -405.43M |
| Net Margin % | -14.07% | -18.73% | -50.73% | -102.03% | -54.43% | -28.03% | -4.21% | -4.17% | -0.41% |
| Net Income Growth % | - | -0.1% | -1.91% | -3.29% | 0.54% | -0.15% | -0.13% | -0.05% | 0.56% |
| Net Income (Continuing) | -107.84M | -118.51M | -345.31M | -1.48B | -677.61M | -782.42M | -882.92M | -925.71M | -405.68M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.21M | 9.97M |
| EPS (Diluted) | -2.08 | -2.29 | -6.67 | -28.01 | -12.56 | -12.28 | -13.40 | -13.12 | -1.34 |
| EPS Growth % | - | -0.1% | -1.91% | -3.2% | 0.55% | 0.02% | -0.09% | 0.02% | 0.9% |
| EPS (Basic) | -2.08 | -2.29 | -6.67 | -28.01 | -12.56 | -12.28 | -13.40 | -13.12 | -1.34 |
| Diluted Shares Outstanding | 51.77M | 51.77M | 51.77M | 52.87M | 53.98M | 63.65M | 65.92M | 70.57M | 302.06M |
| Basic Shares Outstanding | 51.77M | 51.77M | 51.77M | 52.87M | 53.98M | 63.65M | 65.92M | 70.57M | 302.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 463.7M | 414.71M | 990.22M | 909.11M | 1.08B | 1.89B | 1.64B | 1.34B | 1.47B |
| Cash & Short-Term Investments | 451.92M | 398.99M | 971.49M | 878.51M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B |
| Cash Only | 294.53M | 14.82M | 957.09M | 878.51M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B |
| Short-Term Investments | 157.39M | 384.17M | 14.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.31M | 7.85M | 5.25M | 2.53M | 480K | 54.13M | 61.49M | 163.54M | 99.07M |
| Days Sales Outstanding | 395.52 | 452.96 | 281.67 | 63.53 | 14.07 | 707.86 | 107.02 | 268.9 | 36.88 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 3.93M | 9.45M | 16.17M | 6.6M |
| Days Inventory Outstanding | - | - | - | - | - | 431.02 | 156.77 | 193.2 | 82.79 |
| Other Current Assets | 11.22K | 25.18K | 6.42M | 3.95M | 17.31M | 59.26M | 16.6M | 24.54M | 24.63M |
| Total Non-Current Assets | 129.64M | 166.95M | 239.16M | 295.94M | 652M | 1.05B | 1.19B | 1.16B | 1.14B |
| Property, Plant & Equipment | 4.51M | 25.33M | 33.99M | 110.22M | 477M | 854.3M | 650.02M | 957.23M | 905.86M |
| Fixed Asset Turnover | 1.70x | 0.25x | 0.20x | 0.13x | 0.03x | 0.03x | 0.32x | 0.23x | 1.08x |
| Goodwill | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M |
| Intangible Assets | 87.13M | 80.71M | 108.53M | 104.31M | 97.39M | 60.41M | 84.3M | 85.45M | 76M |
| Long-Term Investments | 1.91M | 0 | 0 | 4.62M | 31.77M | 27.84M | 18.53M | 18.95M | 33.86M |
| Other Non-Current Assets | 13.31M | 36.22M | 71.94M | 52.1M | 21.13M | 35.88M | 361.93M | 10.05M | 59M |
| Total Assets | 593.34M | 581.66M | 1.23B | 1.21B | 1.73B | 2.94B | 2.83B | 2.5B | 2.62B |
| Asset Turnover | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.07x | 0.09x | 0.37x |
| Asset Growth % | - | -0.02% | 1.11% | -0.02% | 0.44% | 0.7% | -0.04% | -0.12% | 0.05% |
| Total Current Liabilities | 77.62M | 79.53M | 105.27M | 202.06M | 276.15M | 361.11M | 881.15M | 934.17M | 1.17B |
| Accounts Payable | 156K | 3.82M | 5.08M | 13.08M | 23.36M | 70.86M | 95.56M | 72.44M | 91.97M |
| Days Payables Outstanding | 218.16 | - | - | 2.28K | 4.34K | 7.77K | 1.59K | 865.74 | 1.15K |
| Short-Term Debt | 0 | 0 | 35M | 85M | 44.75M | 39.8M | 510.31M | 606.65M | 769.62M |
| Deferred Revenue (Current) | 121.02K | 6.6K | 0 | 6.6K | 6.58K | 0 | 1000K | 1000K | 1000K |
| Other Current Liabilities | 12.46M | 12.23M | 24.76M | 46.9M | 16.87M | 58.73M | 2.82M | 0 | 0 |
| Current Ratio | 5.97x | 5.21x | 9.41x | 4.50x | 3.91x | 5.22x | 1.86x | 1.44x | 1.26x |
| Quick Ratio | 5.97x | 5.21x | 9.41x | 4.50x | 3.91x | 5.21x | 1.85x | 1.42x | 1.26x |
| Cash Conversion Cycle | - | - | - | - | - | -6.63K | -1.32K | -403.64 | -1.03K |
| Total Non-Current Liabilities | 530.33M | 633.93M | 2.14B | 112.51M | 608.27M | 1.34B | 1.54B | 1.5B | 1.18B |
| Long-Term Debt | 0 | 0 | 0 | 0 | 473.06M | 1.03B | 1.27B | 1.17B | 868.64M |
| Capital Lease Obligations | 472K | 2.88M | 4.46M | 9.21M | 6.08M | 8.25M | 9.14M | 12.92M | 20.79M |
| Deferred Tax Liabilities | 21.76M | 20.16M | 18.56M | 16.96M | 15.36M | 13.75M | 12.15M | 10.55M | 5.37M |
| Other Non-Current Liabilities | 499.36M | 594.93M | 2.09B | 51.25M | 73.57M | 52.34M | 35.33M | 18.3M | 6.27M |
| Total Liabilities | 607.95M | 713.46M | 2.24B | 314.57M | 884.42M | 1.71B | 2.42B | 2.43B | 2.34B |
| Total Debt | 830K | 4.9M | 42.04M | 101.41M | 529.7M | 1.08B | 1.79B | 1.8B | 1.67B |
| Net Debt | -293.7M | -9.92M | -915.04M | -777.11M | -490.28M | -622.6M | 317.09M | 726.3M | 431.92M |
| Debt / Equity | - | - | - | 0.11x | 0.63x | 0.88x | 4.39x | 25.42x | 6.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -35.17x | -2.26x | -1.36x | -136.33x | -106.15x | -51.99x | -16.10x | -9.08x | -5.74x |
| Total Equity | -14.61M | -131.8M | -1.01B | 890.48M | 846.62M | 1.23B | 408.66M | 70.63M | 274.16M |
| Equity Growth % | - | -8.02% | -6.68% | 1.88% | -0.05% | 0.46% | -0.67% | -0.83% | 2.88% |
| Book Value per Share | -0.28 | -2.55 | -19.54 | 16.84 | 15.68 | 19.40 | 6.20 | 1.00 | 0.91 |
| Total Shareholders' Equity | -14.61M | -131.8M | -1.01B | 890.48M | 846.62M | 1.23B | 408.66M | 60.42M | 264.19M |
| Common Stock | 0 | 0 | 63K | 142K | 154K | 178K | 180K | 197K | 214K |
| Retained Earnings | 0 | 0 | -615.82M | -2.1B | -2.77B | -3.56B | -4.44B | -5.37B | -5.77B |
| Treasury Stock | 0 | 0 | -4K | -574 | -4K | -470 | -26.55M | -21.35M | -8K |
| Accumulated OCI | 0 | 0 | 0 | 0 | -509.81M | -550.95M | -518.51M | -504.46M | -510.59M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.21M | 9.97M |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -45.89M | -107.98M | -237.67M | -460.31M | -609.96M | -604.68M | -653.91M | -726.08M | -111.36M |
| Operating CF Margin % | -5.99% | -17.06% | -34.92% | -31.72% | -48.99% | -21.67% | -3.12% | -3.27% | -0.11% |
| Operating CF Growth % | - | -1.35% | -1.2% | -0.94% | -0.33% | 0.01% | -0.08% | -0.11% | 0.85% |
| Net Income | -107.84M | -120.12M | -346.91M | -741.16M | -675.45M | -832.25M | -887.17M | -932.86M | -395.25M |
| Depreciation & Amortization | 164.37K | 12.5M | 18.46M | 3.83M | 27.42M | 28.33M | 62.91M | 93.19M | 93.17M |
| Stock-Based Compensation | 64.99M | 0 | 27.57M | 70.82M | 74.03M | 46.97M | 22.11M | 31.5M | 20.92M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -6.74M | -10.9M | 36.13M | 195.06M | 19.29M | 227.18M | 43.82M | 91.23M | 58.84M |
| Working Capital Changes | 2.15M | 10.53M | 27.08M | 11.14M | -55.25M | -74.91M | 104.41M | -9.15M | 110.97M |
| Change in Receivables | -301K | 556K | 0 | 0 | 0 | -53.97M | -388K | -91.54M | 62.75M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -3.93M | -5.52M | -6.72M | 9.57M |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 24.7M | -23.11M | 19.52M |
| Cash from Investing | -152.61M | -230.35M | 292.81M | -201.33M | -107.37M | -466.52M | -384.61M | 21.92M | -362.04M |
| Capital Expenditures | -3.29M | -20.54M | -48.16M | -77.46M | -249.92M | -435.42M | -203.29M | -46.11M | -24.29M |
| CapEx % of Revenue | 0.43% | 3.25% | 7.08% | 5.34% | 20.07% | 15.6% | 0.97% | 0.21% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -155.42M | -209.81M | -1.29M | -143.48M | -1.55M | -879K | -31.32M | 88.03M | -312.23M |
| Cash from Financing | 435.54M | 58.36M | 860.16M | 442.36M | 1.04B | 1.78B | 619.27M | 368.75M | 314.77M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | -581K | -2.53M | -85.45M | -39.92M | -27.02M | -41.97M | -49.83M | -82.05M | -73.83M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -49.26M | -128.52M | -287.13M | -541.72M | -861.43M | -1.04B | -890.88M | -782.92M | -135.65M |
| FCF Margin % | -6.43% | -20.31% | -42.18% | -37.33% | -69.19% | -37.31% | -4.25% | -3.53% | -0.14% |
| FCF Growth % | - | -1.61% | -1.23% | -0.89% | -0.59% | -0.21% | 0.14% | 0.12% | 0.83% |
| FCF per Share | -0.95 | -2.48 | -5.55 | -10.25 | -15.96 | -16.36 | -13.52 | -11.09 | -0.45 |
| FCF Conversion (FCF/Net Income) | 0.43x | 0.91x | 0.69x | 0.31x | 0.90x | 0.77x | 0.74x | 0.78x | 0.27x |
| Interest Paid | 49K | 257K | 1.89M | 4.27M | 5.93M | 16.81M | 49.85M | 92.35M | 60.56M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -166.28% | -78.02% | -75.18% | -107.45% | -386.25% | -235.17% |
| Return on Invested Capital (ROIC) | - | - | - | -385.48% | -212.03% | -134.72% | -95.28% | -85.96% | -36.9% |
| Gross Margin | 96.6% | 100% | 100% | 85.56% | 84.21% | 88.08% | 89.51% | 86.24% | 97.03% |
| Net Margin | -1406.53% | -1872.85% | -5072.82% | -10202.67% | -5442.62% | -2803.38% | -421.02% | -416.98% | -41.34% |
| Debt / Equity | - | - | - | 0.11x | 0.63x | 0.88x | 4.39x | 25.42x | 6.09x |
| Interest Coverage | -35.17x | -2.26x | -1.36x | -136.33x | -106.15x | -51.99x | -16.10x | -9.08x | -5.74x |
| FCF Conversion | 0.43x | 0.91x | 0.69x | 0.31x | 0.90x | 0.77x | 0.74x | 0.78x | 0.27x |
| Revenue Growth | - | -17.46% | 7.57% | 113.21% | -14.21% | 124.18% | 651.38% | 5.85% | 341.77% |
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported $1.29B in revenue for fiscal year 2024. This represents a 16773% increase from $7.7M in 2016.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) grew revenue by 341.8% over the past year. This is strong growth.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported a net loss of $1.52B for fiscal year 2024.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) has a return on equity (ROE) of -235.2%. Negative ROE indicates the company is unprofitable.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) had negative free cash flow of $505.4M in fiscal year 2024, likely due to heavy capital investments.